clinical trial · NCT03209479
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
Teva Takeda Pharma Ltd.·—·completed·n = 1,332
Multiple SclerosisGlatiramer acetate
brief summary
The purpose of this study is to evaluate the safety and efficacy of Copaxone subcutaneous injection syringe (hereinafter referred to as Copaxone) in patients with multiple sclerosis in the routine clinical setting.
started
Nov 24, 2015
primary completion
Mar 31, 2024
completion
Mar 31, 2024
last updated
Jun 13, 2024
detailed description
The drug being tested in this study is called Glatiramer acetate is being tested to treat people who have Multiple sclerosis. This study will look at the safety and efficacy of Glatiramer acetate in patients with multiple sclerosis in the routine clinical setting.
The study will enroll approximately 1000 patients.
• Glatiramer acetate subcutaneous injection syringe
This multi-center trial will be conducted in Japan.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol